Abstract: Objective To investigate the level of serum hepatocyte growth factor (HGF) in the patients with chronic coronary syndrome (CCS) and its diagnostic value. Methods A total of 89 patients who were diagnosed or suspected as CCS and planned to undergo coronary angiography in our hospital from March to October 2020 were selected, and they were divided into the CCS group (n=56) and the non-coronary heart disease (CHD) group (n=33) according to the results of coronary angiography. The general data of all patients were collected, and the levels of blood lipid, blood glucose, renal function, B-type natriuretic peptide (BNP), left ventricular ejection fraction (LVEF) and HGF were detected and compared between two groups. Propensity score matching (PSM) method was used to control the confounding factors, and binary Logistic regression was used to analyze the influencing factors of CCS. Receiver operating characteristic curve (ROC) was used to evaluate the diagnostic efficacy of HGF for CCS. Results The serum level of HGF in the CCS group was significantly higher than that in non-CHD group(P<0.05). Binary Logistic regression analysis before and after PSM showed that HGF was the risk factor for CCS(OR=1.004,95%CI:1.001-1.007,P<0.05). ROC curve analysis showed that the area under the curve (AUC) of HGF predicting CCS was 0.677 (95%CI:0.567-0.788, P<0.05), with a sensitivity of 48.2% and a specificity of 87.9%. Conclusions The level of serum HGF in the patients with CCS is significantly higher than that in the patients without CHD. The serum level of HGF shows predictive value for CCS, which may be helpful in early identification of CCS.

Key words: hepatocyte growth factor, chronic coronary syndrome, propensity score matching, diagnostic value